tak-385 and Burns

tak-385 has been researched along with Burns* in 1 studies

Other Studies

1 other study(ies) available for tak-385 and Burns

ArticleYear
Re: Kerrington Powell, Michael C. Burns, Vinay Prasad. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint. Eur Urol. 2023;83:101-2.
    European urology, 2023, Volume: 83, Issue:5

    Topics: Burns; Humans; Phenylurea Compounds; Pyrimidinones; United States; United States Food and Drug Administration

2023